AC Immune SA (ACIU)
NASDAQ: ACIU · Real-Time Price · USD
2.220
-0.150 (-6.33%)
At close: Oct 30, 2026, 4:00 PM EDT
2.210
-0.010 (-0.45%)
After-hours: Oct 30, 2026, 7:30 PM EDT
AC Immune Employees
As of December 31, 2025, AC Immune had 122 total employees, including 90 full-time and 32 part-time employees. The number of employees decreased by 50 or 29.07% compared to the previous year. That makes AC Immune the 30,220th largest employer in the world and 3,853rd in the United States.
Employees
122
Change (1Y)
-50
Growth (1Y)
-29.07%
Revenue / Employee
$177,619
Profits / Employee
-$437,794
Market Cap
220.73M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 122 | -50 | -29.07% | 90 | 32 |
| Dec 31, 2024 | 172 | 11 | 6.83% | 133 | 39 |
| Dec 31, 2023 | 161 | 5 | 3.21% | 133 | 28 |
| Dec 31, 2022 | 156 | 7 | 4.70% | 126 | 30 |
| Dec 31, 2020 | 149 | 17 | 12.88% | 125 | 24 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Cabaletta Bio | 158 |
| Keros Therapeutics | 92 |
| BridgeBio Oncology Therapeutics | 88 |
| InflaRx | 65 |
| Lexeo Therapeutics | 63 |
| Pyxis Oncology | 56 |
| Camp4 Therapeutics | 48 |
ACIU News
- 5 weeks ago - AC Immune Transcript: Study result - Transcripts
- 5 weeks ago - AC Immune Press release: Study result - Filings
- 5 weeks ago - AC Immune Slides: Study result - Filings
- 5 weeks ago - AC Immune announces Phase 2 trial of ACI-7104 met primary endpoints - TheFly
- 5 weeks ago - AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104 - GlobeNewsWire
- 2 months ago - AC Immune Slides: Investor presentation - Filings
- 2 months ago - AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 - GlobeNewsWire
- 2 months ago - AC Immune receives fast track designation, clearance for ACI-7104 IND - TheFly